Emyria and UWA ship 14 new MDMA analogues for screening, total raised to 140-plus proprietary compounds
Proactive Investors
Published Oct 18, 2022 10:43
Updated Oct 18, 2022 11:30
Emyria and UWA ship 14 new MDMA analogues for screening, total raised to 140-plus proprietary compounds
Emyria Ltd (ASX:EMD) and its partner, the University of Western Australia (UWA), have shipped the fourth batch of unique MDMA analogues, sending 14 new compounds for safety screening with Eurofins and bringing its library to more than 140 individual analogues.
Emyria and the UWA have been actively generating and screening a drug-discovery pipeline of novel MDMA analogues to identify new chemical compounds and drug candidates with the potential to address unmet needs in mental health and neurological disorders.
Select compounds to begin clinical screening
Five more compounds have also been sent to PsychoGenics in the US to begin advanced preclinical screening, leveraging the US company’s SmartCube™ platform to accelerate development and commercialisation.
Read: Emyria begins US-based preclinical program with leading neuroscience drug discovery research organisation
An Australian Clinical Research Organisation (CRO) will also screen a set of priority compounds for additional metabolic studies in mice, rat and human liver cells, to aid in determining the metabolic half-life of these compounds.
Read more on Proactive Investors AU
Disclaimer
Get The App
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.